Patents by Inventor Joan-En Chang-Lin

Joan-En Chang-Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20230404961
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: March 21, 2023
    Publication date: December 21, 2023
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20210401789
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: May 11, 2021
    Publication date: December 30, 2021
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20210121397
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: January 5, 2021
    Publication date: April 29, 2021
    Inventors: Jeffrey L. EDELMAN, Patrick M. HUGHES, Thomas C. MALONE, Gerald W. DEVRIES, Joan-En CHANG-LIN, Jane-Guo SHIAH, Thierry NIVAGGIOLI, Lon T. SPADA, Wendy M. BLANDA
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 10881608
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 5, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20190365692
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: January 15, 2019
    Publication date: December 5, 2019
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 10213405
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 26, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20190038551
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 7, 2019
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 10076492
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20180021282
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: May 3, 2017
    Publication date: January 25, 2018
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 9668997
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: June 6, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20160354384
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: May 5, 2016
    Publication date: December 8, 2016
    Inventors: CHIN-MING CHANG, JAMES N. CHANG, RHETT M. SCHIFFMAN, R. SCOTT JORDAN, JOAN-EN CHANG-LIN
  • OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES
    Publication number: 20160256424
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Application
    Filed: January 4, 2016
    Publication date: September 8, 2016
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20160250225
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: October 6, 2015
    Publication date: September 1, 2016
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20160199297
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Ophthalmic compositions and methods for treating eyes
    Patent number: 9254324
    Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: February 9, 2016
    Assignee: Allergan, Inc.
    Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 9241918
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: January 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20160015717
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 21, 2016
    Inventors: CHIN-MING CHANG, JAMES N. CHANG, RHETT M. SCHIFFMAN, R. SCOTT JORDAN, JOAN-EN CHANG-LIN
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 9233070
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Enhanced bimatoprost ophthalmic solution
    Patent number: 9155716
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 13, 2015
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • ENHANCED BIMATOPROST OPHTHALMIC SOLUTION
    Publication number: 20150087713
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Application
    Filed: December 5, 2014
    Publication date: March 26, 2015
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin